Command Regenerative Medicine at the Board Level
A rigorous executive credential program that takes biotech and healthcare leaders from scientific literacy to boardroom authority — designing, governing, and defending enterprise regenerative medicine strategies that span tissue engineering, cellular therapies, and precision medicine.
"I designed this program so that when you sit across from a board, a regulator, or an investor, you are not translating the science — you are commanding it."— Pauline Brown Smith, EdD
What you'll learn
What you'll be able to do
- Design a phased enterprise regenerative medicine strategy that integrates tissue engineering, stem cell science, and cellular therapies with measurable organizational outcomes
- Build and defend a Brown Tech Master Portfolio — including a governance plan, enterprise risk register, executive KPI dashboard, and 5/10/20-year innovation roadmap
- Apply regulatory and compliance frameworks (FDA, EMA, GMP/GTP) to real-world regenerative medicine program decisions and safety assessments
- Conduct evidence-based bioethics analyses that distinguish established clinical practice from emerging research and communicate findings to a non-specialist board
- Lead multi-stakeholder engagement across scientific, clinical, investor, and governance audiences — including live executive board presentation and portfolio defense simulations
- Evaluate and prioritize capital investment in biomaterials, translational medicine pipelines, and precision medicine technologies using enterprise risk and ROI methodology
How it works
A school that adapts to you
This isn't a set of static videos. Every lesson is generated live and tuned to where you actually are.
We learn your level
A quick placement check tailors your starting point so you're never bored or lost.
Lessons adapt as you go
Each lesson is written for your pace and your goal, adjusting as your skills grow.
Your AI coach keeps you moving
Checkpoints, feedback, and gentle nudges turn progress into a real result.
The curriculum
What's inside your school
6 modules · 29 lessons
Executive Regenerative Medicine Strategy Design
Equips executives to architect a phased, enterprise-wide regenerative medicine strategy that integrates tissue engineering, stem cell science, and cellular therapies with measurable organizational outcomes.
- 1.1Executive Regenerative Medicine Strategy Capstone OverviewIncluded
- 1.2Phased Enterprise Strategy ArchitectureIncluded
- 1.3Integrating Tissue Engineering, Stem Cell Science, and Cellular TherapiesIncluded
- 1.4Distinguishing Established Clinical Practice from Emerging ResearchIncluded
- 1.5Stakeholder Engagement and Investment PrioritizationIncluded
Governance, Bioethics, and Regulatory Command
Develops executive mastery of governance structures, bioethics frameworks, and the regulatory landscape — FDA, EMA, GMP/GTP — required to lead compliant regenerative medicine programs.
- 2.1Enterprise Governance Plan DesignIncluded
- 2.2FDA, EMA, and GMP/GTP Regulatory FrameworksIncluded
- 2.3Bioethics Analysis for Executive Decision-MakersIncluded
- 2.4Patient Safety Strategy and Risk-Based OversightIncluded
- 2.5Communicating Ethics and Compliance to Non-Specialist BoardsIncluded
Biomaterials, Translational Medicine, and Capital Investment Strategy
Builds executive fluency in evaluating biomaterials platforms and translational pipelines, and applying enterprise risk and ROI methodology to guide capital investment decisions.
- 3.1Biomaterials Innovation and Strategic FrameworkIncluded
- 3.2Translational Medicine Pipeline ManagementIncluded
- 3.3Precision Medicine Technologies and Enterprise IntegrationIncluded
- 3.4Enterprise Risk Register for Regenerative Medicine ProgramsIncluded
- 3.5Capital Investment Prioritization Using ROI and Risk MethodologyIncluded
Executive KPI Dashboard and Innovation Roadmap
Develops the executive measurement infrastructure — KPI dashboards and 5/10/20-year innovation roadmaps — that demonstrate portfolio performance and long-term organizational value creation.
- 4.1Designing the Executive KPI DashboardIncluded
- 4.2Continuous Improvement Systems for Regenerative Medicine ProgramsIncluded
- 4.3Five-, Ten-, and Twenty-Year Regenerative Medicine Innovation RoadmapIncluded
- 4.4Stem Cell Science Roadmap for Executive LeadersIncluded
Brown Tech Master Regenerative Medicine Portfolio
Guides executives through assembling every required portfolio component — strategy blueprint, governance plan, risk register, KPI dashboard, roadmap, and reflective journal — into a cohesive, defensible master portfolio.
- 5.1Enterprise Regenerative Medicine Strategy BlueprintIncluded
- 5.2Governance Plan, Risk Register, and KPI Dashboard IntegrationIncluded
- 5.3Board Presentation Design and Executive CommunicationIncluded
- 5.4Reflective Leadership Journal and Executive Competency NarrativeIncluded
- 5.5Portfolio Completeness Review and Defense PreparationIncluded
Executive Competency Verification and Portfolio Defense Simulation
Culminates the credential with live portfolio defense, case study analysis, and board simulation activities that verify executive mastery across all program outcomes.
- 6.1Regenerative Medicine Case Studies and Evidence-Based RecommendationsIncluded
- 6.2Governance Reviews and Ethics Analyses Under ScrutinyIncluded
- 6.3Safety Assessment and Regulatory Compliance DefenseIncluded
- 6.4Executive Regenerative Medicine Portfolio Defense SimulationIncluded
- 6.5Chapter Summary and Unified Executive Leadership FrameworkIncluded
Who it's for
Is this you?
Chief Medical Officers
CMOs overseeing clinical programs that intersect regenerative medicine need governance command and regulatory fluency to defend safety strategy and ethics positions at the board level.
Biotech C-Suite Executives
CEOs and COOs of biotech firms building or acquiring regenerative medicine programs need a rigorous framework for enterprise strategy design, capital prioritization, and portfolio defense.
Biopharma Program Directors
Directors managing translational medicine pipelines and cellular therapy programs need the investment ROI methodology and risk register discipline to lead credibly at the executive tier.
Hospital & Health System Executives
Hospital C-suite leaders evaluating institutional investment in regenerative medicine need evidence-based decision tools and regulatory literacy to govern safely and compellingly.
Healthcare Investment Strategists
Senior strategists and portfolio decision-makers in healthcare investment need the scientific and regulatory command to evaluate regenerative medicine assets with rigor, not just surface-level due diligence.
Regulatory & Governance Leaders
Executives responsible for FDA, EMA, GMP, and GTP compliance across regenerative medicine programs need the governance architecture and board communication skills this program systematically builds.
Questions
Frequently asked
Your teacher
A note from your teacher
Pauline Brown Smith, EdD
If you are reading this, you are likely already operating at a level where the science briefings are not the problem. You have access to scientific advisors. You can read an abstract. What you may not yet have — and what boards, investors, and regulators are increasingly demanding — is the ability to own the strategic conversation yourself. To design the governance architecture. To defend the risk register. To stand in front of an investment committee and make the case for a cellular therapy pipeline with the precision of someone who has built the framework, not just received the summary.
That gap is what this program was designed to close.
I have built this curriculum for the senior leader who understands that regenerative medicine is not a scientific curiosity sitting in the R&D department — it is an enterprise risk, a capital commitment, a regulatory exposure, and a potential institutional legacy, all at once. Tissue engineering, stem cell science, cellular therapies, precision medicine integration — these are boardroom topics now. The executives who will define the next decade of this field are not the ones who hand the science off. They are the ones who can govern it.
The program is structured around a single, serious deliverable: the Brown Tech Master Portfolio. Every section of the curriculum — regulatory command, bioethics analysis, biomaterials investment strategy, KPI dashboard design, innovation roadmapping — feeds into a body of executive work you will actually defend. Not in a reflective essay. In a simulated portfolio defense that mirrors the conditions of a real board or investment committee presentation. I designed it that way because credential programs that do not pressure-test their outcomes do not produce leaders — they produce participants.
What I will ask of you is rigorous thinking. I will expect you to engage FDA and EMA frameworks not as compliance checklists but as strategic instruments. I will expect your bioethics analyses to hold up under scrutiny from a non-specialist board. I will expect your 5/10/20-year innovation roadmap to reflect the actual landscape of stem cell science and translational medicine — not optimistic generalities. I treat you as a peer, because the work demands it.
If you are ready to move from being briefed on regenerative medicine to being the executive who leads the strategy, governs the program, and defends the portfolio — this is where that transition is made.
— Pauline Brown Smith, EdD
Start your journey today
Join get instant access — learn at your own pace with an AI coach in your corner.
$297/mo
Recurring billing · cancel anytime
Secure checkout · Instant access
- 6 modules, 29 lessons
- AI-adaptive lessons tuned to your level
- Quizzes & checkpoints to lock in progress
- Your own AI learning coach
- Learn on any device, at your pace
- Full access for as long as you're subscribed